Life Sciences Division iterates bullish view on ImmuPharma
Abraham Darwyne
Company News - 2 min read
07:00, 10th September 2019

The Life Sciences Division (TLSD), a specialist investment bank to global life sciences companies, has reiterated its bullish view on ImmuPharma.

ImmuPharma (IMM) FOLLOW a pharmaceutical development company that develops novel medicines, in specialist markets with serious unmet needs, is currently focused on developing its lead asset addressing Lupus: Lupuzor.

The Life Sciences Division, in a note to investors, commented on AstraZeneca’s FOLLOW Anifrolumab and its navigation through a Phase III lupus clinical trial, alluding to the potential of AIM listed ImmuPharma’s LupuzorTM.

Dr. Navid Malik, Head of Life Sciences Research at TLSD, said in a research note: "Lupus still represents a major area of unmet medical need and there is a strong need for safe and efficacious products.”

Dr. Navid adds: “We believe that the recent update for Anifrolumab is positive for the Lupus field, but also reminds us that LupuzorTM could represent a highly successful product if it successfully navigates a second Phase III clinical trial.”

“Now that we understand the target patient group of Lupus patients who respond best to the drug, we see the path to market as being de-risked."

Shares in ImmuPharma fell dramatically after its Phase III Trial last April failed to meet its primary endpoint, but confirmed the safety profile of Lupuzor™, with zero serious adverse events reported.

The fact that Lupuzor is a late stage asset, with a “unique mechanism of action", The Life Sciences Division view it as an important potential treatment for Lupus patients.

Pharmaceutical investors will be closely following the data published from AstraZeneca’s TULIP II study and its implications..

Follow News & Updates from ImmuPharma here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles